Nanoscope Therapeutics’ MOGENRY® BLA Accepted by FDA
|
Nanoscope Therapeutics announced that the U.S. FDA has accepted and filed its Biologics License Application for MOGENRY® (MCO-010), an investigational optogenetic gene therapy for patients with retinitis pigmentosa (RP) and severe vision loss.
Supported by positive Phase 2b/3 RESTORE trial results and long-term follow-up data, MOGENRY demonstrated improvements in visual acuity and sustained benefits. If approved, MOGENRY could become the first gene-agnostic therapy designed to restore vision in patients with severe RP, delivered as a one-time, in-office treatment without the need for genetic testing.
|
Hill Prizes Announce 2026 Research Grant Recipients
|
Lyda Hill Philanthropies and the Texas Academy of Medicine, Engineering, Science and Technology have announced six Texas researchers receiving follow-up grants through the Hill Prizes program. The recipients are advancing research in areas including AI-driven cancer detection, non-hormonal contraception, antiviral therapies, cancer survivorship and drug-resistant tuberculosis. Three of the six researchers are from UT Southwestern Medical Center, highlighting the strength of Texas’ biomedical research and innovation community.
|
Health Wildcatters Announces 2026 Accelerator Cohort
|
Health Wildcatters has announced the 10 startups selected for its 14th accelerator cohort, chosen from nearly 600 applicants across the United States and international markets. The 2026 cohort includes companies from the U.S., Canada, and Israel, with one third of the companies female founded or female led. Through the accelerator, founders will receive funding, mentorship, and access to healthcare executives, investors, and strategic partners, along with programming focused on commercialization, fundraising, and growth.
|
Exploring the Future of North Texas Life Sciences
|
BioNTX was excited to be a part of Bisnow's DFW Life Sciences Summit. Our CEO, Gina Ford, joined a panel of experts and highlighted the rapid growth of the life sciences sector in North Texas and the momentum positioning DFW as a rising clinical and commercial hub. We're grateful to be a part of this conversation and excited to see the continued progress of the North Texas life sciences sector.
|
Join Us This September at the 2026 iC³ Summit
September 24 - 25, 2026
|
The BioNTX iC³ Life Science & Healthcare Innovation Summit is North Texas’s premier convening for the region’s bioscience and healthcare community. Each year, we bring together industry leaders, pioneering researchers, investors, entrepreneurs, and innovators to share insights, explore emerging trends, and collaborate on the next breakthroughs in life sciences and healthcare.
At iC³ 2026, you will have the opportunity to engage with thought leaders, connect with peers, and participate in conversations that are shaping the future of healthcare innovation in North Texas and beyond. Whether you are looking to gain knowledge, showcase your work, or build meaningful partnerships, iC³ provides the platform to make an impact.
|
Thank you for your support
|
Exclusive 1:1 Meetings with Johnson & Johnson Only at iC³
Apply by September 14, 2026
|
Applications are now open for 1:1 meetings with Johnson & Johnson leaders during the 2026 iC³ Life Science & Healthcare Innovation Summit, taking place September 24–25.
Johnson & Johnson is seeking to connect with startups and academic researchers developing next-generation healthcare solutions and exploring potential collaboration opportunities.
Areas of interest include:
- Immunology
- Oncology
- Neuroscience
- Cardiopulmonary
- Data Science & Digital Health (DPDS)
- MedTech
Solutions may address any stage of the healthcare journey, including preparation, prevention, intervention, and recovery.
To take advantage of this opportunity, applicants must be
registered attendees of the 2026 iC³ Life Science & Healthcare Innovation Summit.
|
BIO BREAK: Connect, Collaborate, Innovate
|
BIO BREAK brings the life sciences community together for an evening of connection and conversation. Attendees will have the opportunity to network with peers, share insights on emerging trends, and explore ideas driving collaboration and innovation across the ecosystem. The event is designed to strengthen professional relationships and support a more connected life sciences community in the region.
|
FORT WORTH
October 13, 2026
|
AstraZeneca Reports Positive Phase III Results
for Imfinzi in Small Cell Lung Cancer
|
AstraZeneca’s Phase III DeLLphi-305 trial showed that Imfinzi (durvalumab) plus tarlatamab significantly improved overall survival compared with Imfinzi alone in patients with extensive-stage small cell lung cancer. The combination also improved progression-free survival and response rates, with no new safety concerns identified. The results highlight the potential for this combination to provide a new treatment option for patients with this aggressive form of lung cancer.
|
Colossal Biosciences’ Tasmanian Tiger
Efforts Bolstered by New Research
|
A new study published in Nature Communications is providing fresh insight into the biology of the extinct Tasmanian tiger, suggesting the species was adapted to hunt smaller prey rather than livestock. Researchers found that the thylacine’s distinctive skull and jaw structure differed significantly from wolves and other carnivorous mammals, challenging assumptions that contributed to its persecution and eventual extinction. The findings offer new insight into the species as Colossal Biosciences advances its efforts to bring the Tasmanian tiger back through genetic engineering and de-extinction technology.
|
Island Pharmaceuticals Secures FDA
Regulatory Authorization for Marburg Drug Development
|
Island Pharmaceuticals has secured a Letter of Authorization allowing it to reference comprehensive Marburg-Angola virus natural history data in submissions to the US FDA. The authorization addresses specific FDA feedback and supports the company’s development of Galidesivir under the FDA’s Animal Rule pathway. Island plans to conduct additional non-human primate studies at USAMRIID and Texas Biomedical Research Institute to evaluate dosing and treatment timing following Marburg infection.
|
Johnson & Johnson Receives FDA Approval
for IMAAVY in Rare Blood Disorder
|
Johnson & Johnson announced that the FDA has approved IMAAVY® (nipocalimab-aahu) for adults and children ages 12 and older with warm autoimmune hemolytic anemia (wAIHA). The approval makes IMAAVY the first FDA-approved treatment specifically for wAIHA, addressing a significant unmet need for patients with this rare and potentially life-threatening autoimmune disease. The approval is supported by Phase 2/3 ENERGY trial results showing improved and sustained hemoglobin levels compared with placebo.
|
Solaris Endovascular Reports Positive Results
for Investigational Drug-Eluting Stent
|
Solaris Endovascular announced positive six-month results from its Phase II DEScover study evaluating Solaris DE, an investigational sirolimus-eluting covered stent designed to treat dialysis access dysfunction. Interim results showed 95% target lesion primary patency and 82% access circuit primary patency among patients treated with Solaris DE. The device, which combines a self-expanding stent, electrospun-PTFE membrane, and controlled sirolimus delivery, received FDA Breakthrough Device Designation in May 2026, supporting its continued development as a potential treatment for patients with failing hemodialysis access.
|
GL Chemtec Tackles the Challenges of Biomaterial Scale-Up
|
GL Chemtec is helping companies bridge the gap between promising biomaterial formulations and scalable, manufacturable products. The company integrates polymer chemistry, formulation, analytics and process development to address challenges that can emerge during scale-up, including variability, stability, release performance and manufacturing consistency. Its approach helps development teams build process knowledge early and move complex biomaterial technologies toward GMP and clinical-supply readiness.
|
PSC Biotech Highlights the Importance
of Data Integrity in CDMO Operations
|
PSC Biotech highlights the growing importance of data integrity as pharmaceutical companies expand their use of CDMOs and increasingly complex global supply chains. In a new article, the company examines how strong data governance, quality agreements, risk-based audits and digital solutions can help maintain accurate, reliable and traceable GxP data across outsourced operations. By strengthening oversight and transparency, these practices can help pharmaceutical organizations reduce compliance risks, improve inspection readiness and protect product quality throughout the manufacturing lifecycle.
|
The North Group Brings Intelligence-Driven Security
to North Texas Life Sciences
|
As North Texas’ life sciences ecosystem continues to grow, security challenges are becoming increasingly complex. As BioNTX’s Official Security and Risk Intelligence Partner, The North Group provides 24/7 Global Security Operations Center (GSOC) monitoring that integrates security systems, threat intelligence and real-time analysis to help life sciences organizations identify and respond to potential risks. The North Group’s intelligence-driven approach helps companies protect research, facilities, personnel and critical assets while providing proactive insight into emerging threats.
|
Arlington Earns Three National Economic Development Awards
|
The City of Arlington and Arlington Economic Development Corporation earned three 2026 Excellence in Economic Development Awards from the International Economic Development Council. Honors included a Gold Award for the Arlington Business Certification Program, Silver for the Arlington EDC Annual Report, and Bronze for the E-Space North American Headquarters project. The recognition highlights Arlington’s continued efforts to support local businesses, attract major investment, and advance economic development across the community.
|
UTA Researchers Use AI to Advance
Drug Discovery and Precision Medicine
|
Researchers at The University of Texas at Arlington and UT Southwestern are developing an AI-powered framework to predict gene-gene and drug-drug synergies. By combining deep learning, Bayesian modeling, multi-omics data and high-throughput screening, the team aims to identify promising drug combinations, better understand how they work and accelerate the development of targeted treatments and precision medicine.
|
UT Dallas Students Win National Capstone Design Competition
|
A UTDesign Capstone team from The University of Texas at Dallas won the Student Poster Competition at the 2026 Capstone Design Conference, continuing the university’s strong track record in the national competition. Sponsored by AstraZeneca, the winning project, Operation Clean Sweep, developed a compact robotic vacuum designed to recover valuable pharmaceutical material left behind in manufacturing equipment. The technology combines cameras, remote controls and a sanitary, dust-tight design to reduce manufacturing waste, improve efficiency and enhance worker safety.
|
UT Southwestern Researchers Uncover
New Patterns in Parkinson’s Disease
|
Researchers at UT Southwestern Medical Center have identified a previously unrecognized sequence of abnormal brain activity in patients with Parkinson’s disease, offering new insight into how the condition affects interconnected brain networks. Published in Cell Reports Medicine, the study analyzed brain signals from 23 patients undergoing deep brain stimulation surgery and identified distinct low-beta and high-beta activity with different timing and roles across brain regions. The findings could help guide the development of more precise and responsive deep brain stimulation therapies for Parkinson’s disease.
|
FUNDING & MENTORSHIP OPPORTUNITIES
|
The Harrington Prize for Innovation in Medicine
The Harrington Prize for Innovation in Medicine, presented by the American Society for Clinical Investigation and Harrington Discovery Institute, honors a physician-scientist who has moved science forward with achievements notable for innovation, creativity and potential for clinical application.
Applications closes on September 14, 2026
|
FDA READI-Home Innovation Challenge
The FDA’s READI-Home Innovation Challenge supports innovators developing medical device technologies that can be used in the home setting to help reduce hospital readmissions. Selected participants will have the opportunity to engage with the FDA, gain early regulatory insights, and advance solutions that improve patient care after hospital discharge.
Applications closes on September 30, 2026
|
Upcoming Events & Opportunities
|
TechFW & UNT Health Innovation Forum
Join TechFW and UNT Health for an afternoon of real talk, real expertise, and real pitches from some of North Texas's most exciting med-tech innovators.
September 17th | Fort Worth, TX
|
2026 Fort Worth Healthcare System Summit
The 2026 Fort Worth Healthcare System Summit explores how health, law, ethics, and technology can advance healthcare access in rural, underserved, and resource-constrained communities.
September 22nd | Fort Worth, TX
|
Dutch MedTech & Digital Health Networking Happy Hour
Join NBSO Texas for a networking happy hour connecting an innovative Dutch MedTech & Digital Health delegation with the North Texas life sciences community.
September 28th | Dallas, TX
|
2026 AURP International Conference
Join AURP to connect with 200+ global innovation leaders, explore emerging trends, and build valuable connections across the innovation community.
September 29th - October 1st | Dallas, TX
|
Thank you for your support!
|
|
